Literature DB >> 33954797

Patients' Perception of Vitiligo Severity.

Nanja van Geel1, Charlotte Moock, Marloes Zuidgeest, Sanne Elisabeth Uitentuis, Albert Wolkerstorfer, Reinhart Speeckaert.   

Abstract

Identifying which factors contribute to vitiligo severity and determining their individual weight are important in the management of vitiligo. The aim of this study is to investigate the predictive variables concerning vitiligo severity as perceived by the patients. Based on a questionnaire, several factors that may contribute to the Patient Global Assessment (PtGA) of severity were investigated within a Belgian vitiligo population (n = 291). In addition, possible factors influencing vitiligo severity were scored and ranked. The strongest correlations with the PtGA of severity were found for impact, Dermatology Life Quality Index and disease extent. Based on multivariable regression analyses, 64.7% of PtGA of severity could be predicted by subjective and objective variables, while 32% could be explained by objective clinical features only. Patients considered lesion location, extent and disease activity as the most important contributing factors to severity. Vitiligo severity is determined by objective clinical features, but also, for a significant part, by the perceived impact of the disease.

Entities:  

Keywords:  impact; outcome; patient-reported outcomes; quality of life; severity; vitiligo

Mesh:

Year:  2021        PMID: 33954797      PMCID: PMC9380269          DOI: 10.2340/00015555-3823

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  16 in total

1.  Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative.

Authors:  Nanja van Geel; Janny Lommerts; Marcel Bekkenk; Albert Wolkerstorfer; Cecilia A C Prinsen; Viktoria Eleftheriadou; Alain Taïeb; Mauro Picardo; Khaled Ezzedine; Reinhart Speeckaert
Journal:  J Invest Dermatol       Date:  2016-01-28       Impact factor: 8.551

2.  Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs).

Authors:  Khaled Ezzedine; Maggi Ahmed; Andrea Tovar-Garza; Carla Hajj; Maxine Whitton; Amit Pandya; Saad Altalhab; Julien Seneschal; John Harris; Charles Taieb
Journal:  J Am Acad Dermatol       Date:  2019-02-11       Impact factor: 11.527

3.  Guidelines for the diagnosis and treatment of vitiligo in Japan.

Authors:  Naoki Oiso; Tamio Suzuki; Mari Wataya-Kaneda; Atsushi Tanemura; Miki Tanioka; Tomoko Fujimoto; Kazuyoshi Fukai; Tamihiro Kawakami; Katsuhiko Tsukamoto; Yuji Yamaguchi; Shigetoshi Sano; Yoshihiko Mitsuhashi; Chikako Nishigori; Akimichi Morita; Hidemi Nakagawa; Masako Mizoguchi; Ichiro Katayama
Journal:  J Dermatol       Date:  2013-02-27       Impact factor: 4.005

4.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

Review 5.  Vitiligo.

Authors:  Khaled Ezzedine; Viktoria Eleftheriadou; Maxine Whitton; Nanja van Geel
Journal:  Lancet       Date:  2015-01-15       Impact factor: 79.321

Review 6.  Vitiligo: An Update on Pathophysiology and Treatment Options.

Authors:  Reinhart Speeckaert; Nanja van Geel
Journal:  Am J Clin Dermatol       Date:  2017-12       Impact factor: 7.403

7.  The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool.

Authors:  Camille Salzes; Sophie Abadie; Julien Seneschal; Maxine Whitton; Jean-Marie Meurant; Thomas Jouary; Fabienne Ballanger; Franck Boralevi; Alain Taieb; Charles Taieb; Khaled Ezzedine
Journal:  J Invest Dermatol       Date:  2016-01       Impact factor: 8.551

8.  Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.

Authors:  David Rosmarin; Amit G Pandya; Mark Lebwohl; Pearl Grimes; Iltefat Hamzavi; Alice B Gottlieb; Kathleen Butler; Fiona Kuo; Kang Sun; Tao Ji; Michael D Howell; John E Harris
Journal:  Lancet       Date:  2020-07-11       Impact factor: 79.321

Review 9.  Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.

Authors:  Joseph F Merola; Abrar Qureshi; M Elaine Husni
Journal:  Dermatol Ther       Date:  2018-03-06       Impact factor: 2.851

10.  Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL).

Authors:  Kosar Hedayat; Mojgan Karbakhsh; Maryam Ghiasi; Azadeh Goodarzi; Yousef Fakour; Zahra Akbari; Afsaneh Ghayoumi; Narges Ghandi
Journal:  Health Qual Life Outcomes       Date:  2016-06-07       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.